Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have been diagnosed with Chronic Kidney Disease (CKD) at a moderate to severe stage (stage 3–5), meaning the kidneys are not filtering blood as well as they should
- People who are currently receiving kidney care at the NYU Nephrology outpatient clinic
- People who are able to understand and agree to take part in the study on their own
Who may not be able to join:
- People who have a condition that affects the body's automatic nervous system (the system that controls things like heart rate and digestion), such as Parkinson's disease
- People who have irregular heart rhythms (arrhythmias)
- People who have a heart device such as a pacemaker or defibrillator that may interfere with measuring heart rate patterns — for example, those with a long-term condition called atrial fibrillation
- People who are currently on regular dialysis treatment
- People who have epilepsy
- People who have a heart rate that is already dangerously slow and causing symptoms
- People who have an implanted defibrillator device
- People who have a permanent pacemaker
- People who are not able to give their own consent to participate
- People who are currently incarcerated
- People who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Qandeel Soomro, MD, NYU Langone Health
Phone: (212) 263-7300
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of Patients who Complete 2 Weeks of Intervention; Proportion of Patients who Tolerate Each Full 15-Minute Session; Incidence of Severe Bradycardia following taVNS Use; Incidence of Severe Tachycardia following taVNS Use; Incidence of Syncope following taVNS Use
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.